Veeva Systems Inc. — Form 10-Q Summary
Reporting period: Fiscal first quarter ended April 30, 2023; comparisons are to the three months ended April 30, 2022, unless noted. Amounts are in U.S. dollars.
Business context and financial performance
Veeva provides cloud software, data, analytics, and services, primarily to the life sciences industry. Revenue is reported across Commercial Solutions and R&D Solutions.
| Metric | Q1 FY2024 | Q1 FY2023 | Change |
|---|---|---|---|
| Total revenue | $526.3 million | $505.1 million | +4% |
| Subscription revenue | $414.5 million | $402.6 million | +3% |
| Professional services and other revenue | $111.8 million | $102.5 million | +9% |
| Gross profit / gross margin | $359.7 million / 68% | $365.6 million / 72% | Profit down 2% |
| Operating income / operating margin | $61.5 million / 12% | $127.7 million / 25% | Income down 52% |
| Net income | $131.5 million | $100.1 million | +31% |
| Diluted earnings per share | $0.81 | $0.62 | +31% |
| Cash provided by operations | $505.9 million | $481.0 million | +$24.9 million |
Commercial Solutions generated $284.2 million in revenue, while R&D Solutions generated $242.1 million. Subscription revenue was 79% of total revenue. The filing reports no borrowings; lease liabilities totaled $58.2 million, including current and noncurrent obligations.
Liquidity and cash flow
At April 30, 2023, cash and cash equivalents were $1.09 billion and short-term investments were $2.52 billion, totaling approximately $3.61 billion. Current assets were $4.19 billion and current liabilities were $1.01 billion. Management said available cash, investments, and operating cash flows should meet working capital and capital expenditure needs for at least 12 months.
Operating cash flow increased year over year, primarily due to increased sales and collections, partly offset by higher operating expenses. Veeva noted that Q1 is seasonally its strongest quarter for operating cash inflows and expects cash from operations to be substantially lower in subsequent quarters. It expects FY2024 operating cash flow to be reduced by approximately $90 million due to tax payments associated with the requirement to capitalize and amortize R&D expenses.
Material changes and unusual items
- Operating income declined as expenses rose faster than revenue. Total operating expenses increased 25%, including R&D up 30%, sales and marketing up 16%, and general and administrative up 30%. Total stock-based compensation rose to $90.7 million from $67.1 million.
- Gross margin fell from 72% to 68%, mainly reflecting higher professional-services compensation and travel costs, alongside revenue timing effects from updated customer contract terms.
- Net income benefited from a $39.7 million income tax benefit, compared with a $30.3 million tax provision a year earlier. The effective tax rate was negative 43.3%, primarily because of $64 million in excess tax benefits from equity compensation, largely related to the CEO’s exercise of stock options under a previously announced plan. This benefit is unusual and materially affected the comparison.
- Other income rose to $30.2 million from $2.7 million, primarily due to higher interest income on investment balances and higher rates.
- The company changed master subscription agreements for multi-year orders, generally adding customer termination-for-convenience rights from February 1, 2023. Veeva said this changes revenue recognition timing and will reduce FY2024 revenue; revenue recognized from these orders is generally expected to align with amounts invoiced starting in FY2025. The change also reduced related contract assets.
Outlook, risks, and contingencies
- Management expects FY2024 total and subscription revenue growth rates to decline compared with FY2023, partly because of the contract changes. It expects growth to accelerate in FY2025, with part of that acceleration reflecting the FY2024 revenue reduction. No specific quarterly or annual revenue guidance figures are provided in the filing text presented.
- Management expects FY2024 operating margin to decrease, citing higher planned operating expenses and the expected contract-related revenue reduction. Expenses, stock-based compensation, and near-term subscription-service costs are expected to rise.
- Veeva expects foreign-exchange movements to negatively affect FY2024 revenue. It also highlighted potential customer impacts from reduced life-sciences sales-representative headcount, tighter project scrutiny, customer funding conditions, competition, and industry consolidation.
- Migration of CRM applications from Salesforce to Veeva Vault is a significant execution risk. Early access is intended in 2024, broader availability in 2025, and existing customers must migrate by September 1, 2030. Veeva does not intend to renew its Salesforce agreement when it expires in September 2025.
- Ongoing IQVIA litigation includes claims and counterclaims; expert discovery was expected to conclude by the end of October 2023. The company could not meaningfully estimate potential gains or losses. Medidata’s appeal of a ruling in Veeva’s favor remained pending, and Mednet litigation was in discovery with trial set for early 2024. The filing also describes other proceedings and litigation-related costs.
- Investment portfolio interest-rate risk is material: Veeva estimated an immediate 100-basis-point rate increase would reduce portfolio market value by $28 million. Other key risks include cybersecurity, data privacy and regulatory compliance, third-party infrastructure and data providers, and customer concentration.
Important facts for investors to verify
- How much FY2024 revenue and margin are affected by the new termination-for-convenience contract terms, and whether FY2025 acceleration develops as management expects.
- Whether subscription growth and Commercial and R&D Solutions trends improve, given Q1 subscription growth of 3% and management’s customer-headcount and project-scrutiny concerns.
- How recurring operating cash flow compares with Q1’s seasonally strong collections, including the expected approximately $90 million FY2024 tax-related cash-flow impact.
- Developments in the Salesforce-to-Vault CRM migration and the IQVIA, Medidata, and Mednet legal matters, including any material financial or customer effects.